GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Medicenna Therapeutics Corp (OTCPK:MDNAF) » Definitions » Book Value per Share

MDNAF (Medicenna Therapeutics) Book Value per Share : $0.19 (As of Sep. 2024)


View and export this data going back to 2017. Start your Free Trial

What is Medicenna Therapeutics Book Value per Share?

Medicenna Therapeutics's book value per share for the quarter that ended in Sep. 2024 was $0.19.

During the past 12 months, Medicenna Therapeutics's average Book Value Per Share Growth Rate was -22.80% per year. During the past 3 years, the average Book Value Per Share Growth Rate was -52.80% per year. During the past 5 years, the average Book Value Per Share Growth Rate was -9.40% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the book value growth rate using book value per share data.

During the past 10 years, the highest 3-Year average Book Value Per Share Growth Rate of Medicenna Therapeutics was 100.80% per year. The lowest was -64.70% per year. And the median was -18.20% per year.

Medicenna Therapeutics's current price is $1.2495. Its book value per share for the quarter that ended in Sep. 2024 was $0.19. Hence, today's PB Ratio of Medicenna Therapeutics is 6.51.

During the past 10 years, the highest P/B Ratio of Medicenna Therapeutics was 10.85. The lowest was 0.00. And the median was 0.00.


Medicenna Therapeutics Book Value per Share Historical Data

The historical data trend for Medicenna Therapeutics's Book Value per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Medicenna Therapeutics Book Value per Share Chart

Medicenna Therapeutics Annual Data
Trend Dec15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24
Book Value per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.55 0.57 0.30 0.31 0.06

Medicenna Therapeutics Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Book Value per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.25 0.20 0.06 0.22 0.19

Competitive Comparison of Medicenna Therapeutics's Book Value per Share

For the Biotechnology subindustry, Medicenna Therapeutics's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Medicenna Therapeutics's PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Medicenna Therapeutics's PB Ratio distribution charts can be found below:

* The bar in red indicates where Medicenna Therapeutics's PB Ratio falls into.



Medicenna Therapeutics Book Value per Share Calculation

Medicenna Therapeutics's Book Value Per Share for the fiscal year that ended in Mar. 2024 is calculated as:

Book Value Per Share=(Total Stockholders Equity-Preferred Stock)/Shares Outstanding (EOP)
=(3.84-0.00)/69.64
=0.06

Medicenna Therapeutics's Book Value Per Share for the quarter that ended in Sep. 2024 is calculated as:

Book Value Per Share=(Total Stockholders Equity-Preferred Stock)/Shares Outstanding (EOP)
=(14.80-0.00)/77.04
=0.19

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Theoretically it is what the shareholders will receive if the company is liquidated. Total Stockholders Equity is a balance sheet item and equal to Total Assets less Total Liabilities of the company.

Book value may include intangible items which may come from the company's past acquisitions. Book value less intangibles is called Tangible Book.


Medicenna Therapeutics  (OTCPK:MDNAF) Book Value per Share Explanation

Usually a company's book value and Tangible Book per Share may not reflect its true value. The assets may be carried on the balance sheets at the original cost minus depreciation. This may underestimate the true economic values of the assets. It also may over-estimate their true economic value because the assets can become obsolete.

For financial companies such as banks and insurance companies, their assets may be reported in current market value of the assets owned. Book values of financial companies are more accurate indicator of the economic value of the company.


Medicenna Therapeutics Book Value per Share Related Terms

Thank you for viewing the detailed overview of Medicenna Therapeutics's Book Value per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Medicenna Therapeutics Business Description

Traded in Other Exchanges
Address
2 Bloor Street W., 7th Floor, Toronto, ON, CAN, M4W 3E2
Medicenna Therapeutics Corp is a Canada-based immuno-oncology company. Its principal business activity is the development and commercialization of IL-2, IL-4, and IL13 Superkines and Empowered Superkines for the treatment of cancer and other diseases. Its pipeline candidates include MDNA55 for recurrent glioblastoma multiforme (rGBM), MDNA11 for Cancer immunotherapies, MDNA209 for Autoimmune Diseases, MDNA413 for Cancer immunotherapies, and MDNA132 for Solid Tumors, BiSKITs represents the novel platform comprised of Bifunctional SuperKine ImmunoTherapies.